What is Rhaeos?
Born from the prestigious John A. Rogers Research Group at Northwestern University, Rhaeos specializes in the development of sophisticated wearable sensors designed to monitor chronic and complex health conditions. The company's flagship innovation, the FlowSense noninvasive wireless sensor, represents a significant leap forward in the management of hydrocephalus. By leveraging deep-tech engineering and clinical rigor, Rhaeos is carving out a distinct niche in the medtech landscape, bridging the gap between academic research and scalable, patient-centric medical solutions. The company's strategic roadmap is supported by a diverse coalition of institutional, public, and private backers, reflecting its broad appeal across the healthcare innovation ecosystem.
How much funding has Rhaeos raised?
Rhaeos has raised a total of $12.7M across 2 funding rounds:
Angel/Seed
$2.2M
Series A
$10.5M
Angel/Seed (2021): $2.2M with participation from Creative Ventures, Portal Innovations, and Lateral Capital
Series A (2023): $10.5M led by Lateral Capital, Steele Foundation for Hope, and Creative Ventures
Key Investors in Rhaeos
Creative Ventures
Creative Ventures is a method-driven venture capital firm that focuses on global-scale challenges, investing in scalable technologies that address existing market demands with rigorous technical and financial oversight.
Portal Innovations
Portal Innovations acts as a venture development engine and life sciences VC firm, providing early-stage biotech and medtech startups with capital, lab infrastructure, and strategic guidance.
Lateral Capital
Lateral Capital is a mission-driven fund that partners with visionary entrepreneurs, offering flexible and patient capital to support growth from seed stages through to maturity.
What's next for Rhaeos?
With the recent infusion of capital, Rhaeos is poised to scale its clinical operations and refine its go-to-market strategy for the FlowSense platform. The company's trajectory suggests a focus on regulatory milestones and expanded clinical trials, essential steps for achieving widespread adoption in the pediatric and chronic care markets. As the firm moves beyond its early-stage development phase, the emphasis will likely shift toward manufacturing optimization and strategic partnerships to ensure the long-term viability of its wearable sensor technology. Investors remain focused on the company's ability to translate its robust research pipeline into tangible, life-improving medical outcomes.
See full Rhaeos company page
